Phaseline

Targets › IL13RA1

IL13RA1 (Interleukin-13 receptor subunit alpha-1): drug programs, companies and trials

1 program from 1 company in 4 trials: 4 Phase 1; Oncology; next expected readout Dec 2027.

Binds with low affinity to interleukin-13 (IL13). Together with IL4RA can form a functional receptor for IL13. (UniProt, P78552)

Open in Phaseline: the race on IL13RA1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
M.D. Anderson Cancer CenterCytokine-treated Veto Cells
CAR-T/CAR-NK cell therapy targeting IL-13 receptor alpha-1 and EGFvIII on glioblastoma cel
IL13RA1, EGFR, IL21, TGFBR2, NR3C1, TROP2Phase 1Acute Lymphoblastic Leukemia; Acute Myeloid Leukemia; Phase 1; Colorectal CancerDec 2027

Conditions

Acute Lymphoblastic Leukemia (1) Acute Myeloid Leukemia (1) Phase 1 (1) Colorectal Cancer (1)

Modalities

mixed (1)

Companies

M.D. Anderson Cancer Center (1)

Related targets

EGFR (1) IL21 (1) TGFBR2 (1) NR3C1 (1) TROP2 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.